239 related articles for article (PubMed ID: 30895635)
1. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
[TBL] [Abstract][Full Text] [Related]
2. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
[TBL] [Abstract][Full Text] [Related]
3. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Abinusawa A; Tenjarla S
Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
[TBL] [Abstract][Full Text] [Related]
4. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
[TBL] [Abstract][Full Text] [Related]
5. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
6. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
7. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
Matthis AL; Zhang B; Denson LA; Yacyshyn BR; Aihara E; Montrose MH
Inflamm Bowel Dis; 2016 Aug; 22(8):1793-802. PubMed ID: 27416043
[TBL] [Abstract][Full Text] [Related]
8. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis.
Hausmann M; Paul G; Menzel K; Brunner-Ploss R; Falk W; Schölmerich J; Herfarth H; Rogler G
Z Gastroenterol; 2008 Mar; 46(3):259-65. PubMed ID: 18322880
[TBL] [Abstract][Full Text] [Related]
9. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
10. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
van de Meeberg MM; Schultheiss JPD; Oldenburg B; Fidder HH; Huitema ADR
Digestion; 2020; 101(3):245-261. PubMed ID: 31013494
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
12. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
13. Alteration of Fungal Microbiota After 5-ASA Treatment in UC Patients.
Jun X; Ning C; Yang S; Zhe W; Na W; Yifan Z; Xinhua R; Yulan L
Inflamm Bowel Dis; 2020 Feb; 26(3):380-390. PubMed ID: 31750918
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy.
Schierová D; Březina J; Mrázek J; Fliegerová KO; Kvasnová S; Bajer L; Drastich P
Cells; 2020 Oct; 9(10):. PubMed ID: 33066233
[TBL] [Abstract][Full Text] [Related]
15. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis.
Swidsinski A; Loening-Baucke V; Bengmark S; Lochs H; Dörffel Y
Inflamm Bowel Dis; 2007 Jan; 13(1):51-6. PubMed ID: 17206639
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
[TBL] [Abstract][Full Text] [Related]
17. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
Nagahori M; Kochi S; Hanai H; Yamamoto T; Nakamura S; Omuro S; Watanabe M; Hibi T;
BMC Gastroenterol; 2017 Apr; 17(1):47. PubMed ID: 28390410
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
[TBL] [Abstract][Full Text] [Related]
19. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.
Magnusson MK; Strid H; Sapnara M; Lasson A; Bajor A; Ung KA; Öhman L
J Crohns Colitis; 2016 Aug; 10(8):943-52. PubMed ID: 26896085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
